A comprehensive literature search was conducted to obtain previously published resistance associated mutations for bedaquiline, clofazimine and linezolid for Mycobacterium tuberculosis. Where possible, mutation frequencies for these three drugs were also identified. This catalog of previously published mutations could serve as a reference for comparing mutations associated with either in vitro or clinical resistant mutants. The usage of these data was seen in our study relating to approaches for resistance mutant creation (in vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants in press). Previously published mutations for clofazimine were described in the rv0678 and rv1979c genes, for bedaquiline in atpE, rv0678 and rv2535c (pepQ) genes and for linezolid in the rplC and rrl genes.
Specifications

Value of the data
The data pertaining to genetic variants for bedaquiline, clofazimine and linezolid resistance are vital for understanding drug mechanisms of action.
A catalog such as this may prevent data replication and serve as a comparator or reference for other studies related to resistance-associated mutation.
The combined data of the resistance-associated variants could provide a starting point for the design of molecular susceptibility tests.
Data
The data in this article includes previously published mutations identified in both in vitro (Tables 1 and 3)  as well as clinical isolates (Tables 2 and 4 ) associated with bedaquiline, clofazimine or linezolid resistance. Data were filtered according to the type of mutation identified and the gene in which the mutation occurred. Where available the in vitro approach used to generate the mutant, any information around the strain the mutants were derived from, the mutant MIC value as well as the article from which the data was derived from were included in the data. As bedaquiline-and clofazimine-resistant isolates tend to harbor rv0678 mutations, data for these mutants were presented together. The final data table (Table 5 ) describes previously published mutation frequencies. A diversity of mutations were identified in the rv0678 gene and were scattered along the gene. For the atpE gene, hotspots have been identified at positions 28 and 63. Mutations in the rplC and rrl target genes appear to be associated with either high or low-level linezolid resistance respectively. Four mutations in rv2535c were identified in in vivo bedaquiline and clofazimine resistant isolates. Rv1979c mutations were found in clinical pre-XDR and XDR isolates. 
4-8x MIC Mutations described in rv0678, atpE and rv1979c genes. A dash (-) is used to indicate where no data was available. WT-wild type, no variants detected. MGIT-MGIT960 platform used to determine MIC. BMD-Broth Micro Dilution method used to determine MIC. BDQ-Bedaquiline. CFZ-Clofazimine. Mutations described in rrl and rplC genes. A dash (-) is used to indicate where data was not available. G2447T -acquired resistance during treatment 
Experimental design, materials and methods
A catalog was compiled of mutations observed for in vitro, in vivo and clinical M. tuberculosis strains resistant to bedaquiline, clofazimine and linezolid as reported in studies that were identified through a comprehensive literature search. This was done by searching for combinations of each drug (or drug class) together with terms like "resistant", "resistance", "mutant", "mutations" as well as "Mycobacterium tuberculosis". Related and citing articles were also reviewed. The articles were then analyzed on the basis of the approach used and the mutations documented. Mutations were delineated as arising from either in vivo or clinical and in vitro. A dash (-) is used to indicate where data was not available.
